Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
OTC:IDXG
Price:
1.42 USD
-3.4%
Market Closed
Updated:
Jun 11, 2024
Interpace Biosciences Inc
Accounts Receivables
|
Interpace Biosciences Inc
Accounts Receivables Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Interpace Biosciences Inc
OTC:IDXG
|
Accounts Receivables
$5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
|
DaVita Inc
NYSE:DVA
|
Accounts Receivables
$2.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accounts Receivables
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
CVS Health Corp
NYSE:CVS
|
Accounts Receivables
$10.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
2%
|
|
|
Cigna Corp
NYSE:CI
|
Accounts Receivables
$20.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accounts Receivables
$2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
See Also
What is Interpace Biosciences Inc's Accounts Receivables?
Accounts Receivables
5m
USD
5m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Accounts Receivables amounts to 5m USD.
What is Interpace Biosciences Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-10%
-10%
Over the last year, the Accounts Receivables growth was 7%. The average annual Accounts Receivables growth rates for Interpace Biosciences Inc have been -14% over the past three years , -15% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
